Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage : A randomised, double blind, placebo-controlled crossover trial. / Løn, Nina; Engel, Sara; Damholt, Anders; Mortensen, Brynjulf; Haaber, Anne B.; Wellejus, Anja; Knop, Filip K.
In: Alimentary Pharmacology and Therapeutics, Vol. 59, No. 3, 2024, p. 341-349.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage
T2 - A randomised, double blind, placebo-controlled crossover trial
AU - Løn, Nina
AU - Engel, Sara
AU - Damholt, Anders
AU - Mortensen, Brynjulf
AU - Haaber, Anne B.
AU - Wellejus, Anja
AU - Knop, Filip K.
N1 - Publisher Copyright: © 2023 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
PY - 2024
Y1 - 2024
N2 - Background: Gastric and duodenal ulcerations are common during multiple-dosing aspirin treatment, such as for prevention of cardiovascular disease. On capsule endoscopy, oral administration of the bacterial strain Bifidobacterium breve Bif195 (DSM 33360) reduced the risk of aspirin-induced small intestinal damage, without affecting cyclo-oxygenase-2 (COX-2) inhibition. Aim: To evaluate endoscopically the effect of Bif195 on aspirin-induced stomach and duodenal mucosal damage. Methods: Twenty-five healthy volunteers underwent two intervention periods in a randomised, double-blind, placebo-controlled crossover design including four gastroduodenoscopies and 6 weeks washout. Each intervention was a 4-week oral co-treatment of aspirin 300 mg daily and Bif195 (≥1011 colony-forming units daily) or placebo. Primary endpoint was change in Lanza score - ranging from 0 (normal mucosa) to 4 (>10 erosions or ulcer). Results: All 25 participants (56% females); age 27.3 (±4.8) years; BMI 23.2 (±3.4) kg/m2, completed the trial exhibiting significant increases in Lanza scores during placebo treatment as compared to baseline. Bif195 reduced gastric Lanza score with an odds ratio of 7.2 (95% confidence interval 1.72–30.08, p = 0.009) compared to placebo with no related adverse events. There were no significant changes in Lanza scores in the duodenum. Conclusions: Bif195 reduces aspirin-induced gastric mucosal damage and may serve as a safe supplement during multiple-dosing aspirin treatment.
AB - Background: Gastric and duodenal ulcerations are common during multiple-dosing aspirin treatment, such as for prevention of cardiovascular disease. On capsule endoscopy, oral administration of the bacterial strain Bifidobacterium breve Bif195 (DSM 33360) reduced the risk of aspirin-induced small intestinal damage, without affecting cyclo-oxygenase-2 (COX-2) inhibition. Aim: To evaluate endoscopically the effect of Bif195 on aspirin-induced stomach and duodenal mucosal damage. Methods: Twenty-five healthy volunteers underwent two intervention periods in a randomised, double-blind, placebo-controlled crossover design including four gastroduodenoscopies and 6 weeks washout. Each intervention was a 4-week oral co-treatment of aspirin 300 mg daily and Bif195 (≥1011 colony-forming units daily) or placebo. Primary endpoint was change in Lanza score - ranging from 0 (normal mucosa) to 4 (>10 erosions or ulcer). Results: All 25 participants (56% females); age 27.3 (±4.8) years; BMI 23.2 (±3.4) kg/m2, completed the trial exhibiting significant increases in Lanza scores during placebo treatment as compared to baseline. Bif195 reduced gastric Lanza score with an odds ratio of 7.2 (95% confidence interval 1.72–30.08, p = 0.009) compared to placebo with no related adverse events. There were no significant changes in Lanza scores in the duodenum. Conclusions: Bif195 reduces aspirin-induced gastric mucosal damage and may serve as a safe supplement during multiple-dosing aspirin treatment.
U2 - 10.1111/apt.17817
DO - 10.1111/apt.17817
M3 - Journal article
C2 - 38036761
AN - SCOPUS:85178476966
VL - 59
SP - 341
EP - 349
JO - Alimentary Pharmacology and Therapeutics, Supplement
JF - Alimentary Pharmacology and Therapeutics, Supplement
SN - 0953-0673
IS - 3
ER -
ID: 379705573